TALS - Talaris presents data on COVID outcomes in kidney transplant patients treated with FCR001

Talaris Therapeutics (NASDAQ:TALS) presented new data on COVID-19 outcomes among living donor kidney transplant (LDKT) patients treated in the company’s phase 2 trial of investigational cell therapy product FCR001. Data presented at the 2022 Cutting Edge of Transplantation meeting. Researchers at Northwestern University conducted a retrospective chart review of patients in the phase 2 study, examining COVID-19 infection rates, effects of COVID-19 infection, and evidence of antibody response to vaccination. Low rate of COVID-19 infection was observed in vaccinated, durably chimeric patients off immunosuppression. There was no evidence of acute kidney injury or impaired renal function in FCR001-treated patients with COVID-19 infection. No patients lost chimerism as a result of COVID-19 vaccination or infection.

For further details see:

Talaris presents data on COVID outcomes in kidney transplant patients treated with FCR001